- Citi's 2024 Virtual Oncology Leadership Summit
February 21, 2024 , fireside chat at12:00 pm EST
Leerink Global Biopharma Conference March 12, 2024 , fireside chat at1:40 pm EDT
Barclays Global Healthcare Conference March 13, 2024
H.C. Wainwright 2nd AnnualCell Therapy Virtual Conference March 26, 2024 , fireside chat at11:30 am EDT
For more information and links to available webcasts, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for 30 days after the events.
About Caribou’s novel next-generation CRISPR platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”) that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.
About
Investors:
investor.relations@cariboubio.com
Media:
media@cariboubio.com
Source:
2024 GlobeNewswire, Inc., source